Article info

Download PDFPDF

207 Claudin18.2-targeting CAB-T cells have superior safety over traditional CAR-T, while maintaining potent in vivo anti-tumor efficacy
Free

Authors

Citation

Chai J, Huang W, Peng S, et al
207 Claudin18.2-targeting CAB-T cells have superior safety over traditional CAR-T, while maintaining potent in vivo anti-tumor efficacy

Publication history

  • First published November 7, 2022.
Online issue publication 
November 07, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.